Comparison of the Four Major PrEP Trials (From document research by Terry Michael, as of May 31, 2014.)

Name of trial, funding source/s, drugs used.	Number of subjects in trial. Description and size of cohorts.	Geographical location/s*** of subjects.	Time frame of study and report release date.	Findings claimed by investigators	Alternative view of what the data demonstrate.
iPREX PrEP NIAID & Gates F. Truvada# /TDF-FTC Placebo	2,499 total MSM* All HIV- Truvada =1,251 Placebo = 1,248 2/5 prostitutes	Peru (56%) plus Ecuador, Brazil, Thailand, S. Africa, US (9% SF/Boston) ***91% 3rd World***	Enrolled between July '07 - Dec. '09; halted early May '10 Article NEJM+ 12/30/10	Truvada =36 Sero-Conv. Placebo =64 Sero-Conv. formula^: 64-36/64 = 44% claimed as greater protect. than placebo	97% of Truvado cohort ***did not*** sero-conv.; 95% of placebo cohort ***did not*** sero-conv. **2% *"better"* with drugs?** Buried in report is claim 90% + better for absolute adherence.##
Partners PrEP Gates F. Viread#/TDF Truvada# /TDF-FTC Placebo	4,747 hetero *couples*, sero-discordant** Viread=1,584 Truvada = 1,579 Placebo = 1,584	Kenya and Uganda ***100% 3rd world***	Enrolled between July'08-Nov.'10 halted early, 5/31/11 Article NEJM 8/2/12	Viread x=17 (67%) Truvada x=13 (75%) Placebo = 52 formula^: 52-x/52 = % claimed "more protected"	99% of drugged cohorts did not sero-conv. 97% of placebo cohort did not sero-conv. **2% *"better"* with drugs?**
~~**Fem-PrEP**~~ Gates F. & USAID Truvada#/TDF-FTC Placebo	2,120 female HIV- Truvada=1,024 Placebo = 1,032 (had planned 3,900)	South Africa, Kenya, Tanzania ***100% 3rd world***	Enrollment began 2009, **halted 4/2011** Halting explained CROI# March 2012	Truvada = 33 (3.2% Sero-C.) Placebo = 35 (3.4% Sero.C) "Protection" statist. **identical** formula: x/cohort size	96.8% Truvada cohort and 96.6% of placebo cohort did not sero-conv. **two-tenths of 1% "better"?**
~~**VOICE PrEP**~~ NIAID Truvada#/TDF-FTC Viread#TDF; Viread gel Placebo tabs & gel	5,029 female HIV- Truvada=994; Viread=1002; Viread gel=1003; placebo tab=1008; placebo gel=1003	South Africa (80%), Uganda, Zimbabwe ***100% 3rd world***	Enrollment between 9/'09 - 6/'11; **halted 10/2011.** Halting explained CROI 3/'13	Sero-C's:Truv.=61, Viread =60, placebo tabs=60. ***Equal*** "protection." Viread gel=61, placebo gel=70; statist. insig. difference	94% Truv., 94% Viread and 94% placebo tab cohorts did not Sero.C. 94% Viread gel and 93% placebo gel did not Sero-C. 1% **"better"?**

NOTES.....

NIAID = Nat. Institute of Allergy and Infectious Diseases; Gates F. = Bill and Melinda Gates Foundation;
USAID = U.S. Agency for International Development. Truvada = TDF-FTC = tenofovir disoproxil fumarate and emtricitabine.
Viread = TDF = tenofovir disoproxil fumarate. Drugs are chemotherapy, called "anti-retroviral treatments" or ARVs or ARTs.

# Gilead donated ALL drugs used in all trials ~~X~~ = HALTED when results didn't match conf. biases of investigators	*MSM = Men who have Sex with Men. ** 1 partner HIV+ and 1 HIV-	*** All funded by U.S. entities, with U.S. drugs, seeking U.S. FDA approval, yet almost 100% 3rd world subjects??	#Conf. on Retroviruses and Opportunistic Infections +New England Journal of Medicine	^ Placebo sero-con.'s minus drug sero-con's divided by placebo Sero-Cs = % "less" sero-con. than placebo	##This 90%+ is a non-real world condition of not missing single dose, yet news stories cite it instead of already spurious 44%

NOTE: iPREX trial (gay men,) and Partners PrEP (hetero discordant couples) were at the heart of Gilead's effort to obtain "fast-track" FDA approval for Truvada for HIV *negatives*. Paying a "user fee," Gilead got 6-month action -- a "fast track"-worthy emergency use for non-"positive," non-ill individuals, for a drug retailing $12-$14,000/year? Even orthodox HIV experts warn against "premature" use of toxic chemicals in *positives*, because of adverse effects over time to liver, kidney and heart, meaning 10 or 15 years, often less. None of the PrEP trials lasted much more than a year or two. Thus, there was no evidence on long-term adverse effects in negatives. The trials were a collusion between Gilead, NIAID, FDA and CDC, which put its stamp of approval on prescription of Truvada for PrEP in May 2014. It was all about the money, subjecting gay men, IV drug users, 3rd world people, and African Americans (the "risk groups") to lethal chemotherapy.